Document resource
Introduction The Armadillo catheter incorporates a dual-mode design that allows operator-controlled transitions between tracking and support, providing variable stiffness and enhanced navigability. Its 0.072’ inner diameter, radial-base, hydrophilic coating length facilitates distal access in small-caliber vessels and have been primarily optimized for transradial use. We describe a novel application of the Armadillo catheter via a transfemoral approach for middle meningeal artery (MMA) embolization in the treatment of chronic subdural hematomas (cSDHs), and evaluate its safety and performance in a large series.Methods An IRB-approved, prospectively maintained database of the senior authors’ cases was retrospectively reviewed to identify patients who underwent MMA embolization utilizing the Armadillo catheter transfemorally for access.Results From May 2022 to August 2025, there were 256 MMA embolizations across 138 patients utilizing the Armadillo catheter through a transfemoral approach. The average age of the patients was 74 ± 0.8 years, with 75 of them being female (54%). The cohort demographics were majority White (62%) and Hispanic (29%). Average SDH thickness was 8.5 ± 0.4 mm with an average midline shift 2.1 ± 0.2 mm.Procedural success was obtained in 137 patients (99%) with only one procedure aborted due to common carotid artery tortuosity and anatomy. No iatrogenic vessel injury occurred. No repeat embolization was required. No periprocedural severe complications or mortality occurred.Conclusion This large series demonstrates that the Armadillo catheter provides a safe and effective platform for transfemoral MMA embolization of chronic subdural hematomas. The catheter’s functionality and distal trackability through external carotid artery branches proved advantageous for achieving stable positioning for liquid embolic delivery.Disclosures J. Collard de Beaufort: None. J. Campos: 2; C; Rapid Medical. K. Van Orden: None. M. Arthur: None. B. Polis: None. J. Hamilton: None. B. Meyer: None. D.A. Zarrin: None. F. Laghari: None. N. Beaty: 6; C; Medtronic Neurovascular, Stryker Neurovascular, CMO of NeuroMedica. G. Colby: 2; C; Medtronic Neurovascular, MicroVention-Terumo, Rapid Medical, Cerenovus, Stryker Neurovascular. A.L. Coon: 2; C; Medtronic Neurovascular, MicroVention-Terumo, Stryker Neurovascular, Cerenovus, Rapid Medical, Avail MedSystems, Imperative Care, Deinde, InNeuroCo, Q’apel. 6; C; MicroVention-Termo, Stryker Neurovascular, Medtronic Neurovascular.